Literature DB >> 24619814

The bioavailability of different zinc compounds used as human dietary supplements in rat prostate: a comparative study.

Andrzej Sapota1, Adam Daragó, Małgorzata Skrzypińska-Gawrysiak, Marzenna Nasiadek, Michał Klimczak, Anna Kilanowicz.   

Abstract

The normal human prostate accumulates the highest levels of zinc (Zn) of any soft tissue in the body. The pool of zinc available to the body is known to significantly decrease with age. It is suggested that dietary Zn supplementation protects against oxidative damage and reduces the risk of cancer. Zinc sulfate and zinc gluconate were the most frequently mentioned in per os administration in studies on Zn supplementation. The major aim of the study was to compare the bioavailability of different Zn compounds (sulfate, gluconate and citrate) in the prostate after their daily administration to male rats at three different doses (3.0; 15.0; and 50.0 mg Zn/kg b.w.) for 30 days. The results show that bioavailability in the prostate differs significantly between individual zinc preparations. A significantly elevated Zn concentration in the dorso-lateral lobe of the prostate, compared to controls, was found in the rats supplemented with two compounds only: zinc gluconate and zinc citrate. However, after administration of zinc gluconate, this effect occurred even at the lowest dose. The lowest zinc bioavailability in the prostate was found in the rats administered zinc sulfate: no significant Zn increase was seen in particular zones of the prostate. To sum up, the use of zinc gluconate is worth considering as a possible means of zinc supplementation in men.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24619814     DOI: 10.1007/s10534-014-9724-9

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   2.949


  7 in total

1.  Zinc inhibits the reproductive toxicity of Zearalenone in immortalized murine ovarian granular KK-1 cells.

Authors:  Yijia Li; Xiaoyun He; Xuan Yang; Kunlun Huang; Yunbo Luo; Liye Zhu; Yuzhe Li; Wentao Xu
Journal:  Sci Rep       Date:  2015-09-23       Impact factor: 4.379

2.  The Effect of Zinc and Selenium Supplementation Mode on Their Bioavailability in the Rat Prostate. Should Administration Be Joint or Separate?

Authors:  Adam Daragó; Andrzej Sapota; Marzenna Nasiadek; Michał Klimczak; Anna Kilanowicz
Journal:  Nutrients       Date:  2016-10-04       Impact factor: 5.717

Review 3.  Linking cellular metabolism and metabolomics to risk-stratification of prostate cancer clinical aggressiveness and potential therapeutic pathways.

Authors:  Eric Eidelman; Hemantkumar Tripathi; De-Xue Fu; M Minhaj Siddiqui
Journal:  Transl Androl Urol       Date:  2018-09

Review 4.  Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations.

Authors:  Dominique Reed; Komal Raina; Rajesh Agarwal
Journal:  NPJ Precis Oncol       Date:  2018-07-25

5.  Antidepressant, Anxiolytic and Neuroprotective Activities of Two Zinc Compounds in Diabetic Rats.

Authors:  Christiane Leite Cavalcanti; Maria Conceição Rodrigues Gonçalves; Adriano Francisco Alves; Emmanuel Veríssimo de Araújo; Jader Luciano P Carvalho; Priscilla Paulo Lins; Raquel Coutinho Alves; Naís Lira Soares; Liana Clebia Morais Pordeus; Jailane Souza Aquino
Journal:  Front Neurosci       Date:  2020-01-21       Impact factor: 4.677

6.  Chelation of Zinc with Biogenic Amino Acids: Description of Properties Using Balaban Index, Assessment of Biological Activity on Spirostomum Ambiguum Cellular Biosensor, Influence on Biofilms and Direct Antibacterial Action.

Authors:  Alla V Marukhlenko; Mariya A Morozova; Arsène M J Mbarga; Nadezhda V Antipova; Anton V Syroeshkin; Irina V Podoprigora; Tatiana V Maksimova
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-09

Review 7.  Dietary Phytochemicals in Zinc Homeostasis: A Strategy for Prostate Cancer Management.

Authors:  Chandra K Singh; Gagan Chhabra; Arth Patel; Hao Chang; Nihal Ahmad
Journal:  Nutrients       Date:  2021-05-30       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.